Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives. - Wikidata - wikimedia - TriplyDB

Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.

Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.

http://www.wikidata.org/entity/Q38685278

about

Inflammatory microenvironment in the initiation and progression of bladder cancer.Pembrolizumab in the treatment of advanced urothelial cancer.Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields.A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma.Immune Checkpoint Blockade in Breast Cancer Therapy.Can bladder preservation therapy come to the center stage?Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study.Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-Seq.Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies.Update on the Treatment of Metastatic Urothelial Carcinoma.Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer

P2860

Q46779353-8765C5A1-E975-4E01-9E3B-732EEA09F0FD Q47345366-8DC0E8B6-32D9-4B5C-BA25-1E68A26597FB Q47440377-75233142-A0EA-44BC-BA40-6CB33D480521 Q47711163-0B986EC4-BEDB-4193-9103-0AD0874034DA Q48154177-753F3218-D2E6-4A84-B95C-E6B99C1DF967 Q48556375-FB136C20-8F0E-4399-8472-01D5590E0749 Q49684699-9A3BCEAF-A10E-4A80-8CA9-2EEED58D9E36 Q49821320-81FAD8EC-C443-4577-AFE5-BF0A019A4F01 Q55041956-768D12C7-EE85-42F7-B9FE-8C20D0F44135 Q55081994-9AC96B3E-0508-482A-85FB-D2A9A774D791 Q55454917-3072A7C4-0D37-4EA9-B630-328FB233F9AF Q55510540-9292141E-2DF6-45B4-8439-54DFB0952C3C Q58795373-A100E51B-CE03-4818-9AA0-AC1F66401922

P2860

Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.

http://www.wikidata.org/entity/Q38685278

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.

@en

type

label

Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.

@en

prefLabel

Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.

@en

P1433

Q38685278-1520BB9C-5698-4DFF-B80F-78E6080947AA

P1476

Q38685278-EC946B4C-26F6-4BDF-9F3F-0955DAB36B3D

P2093

Q38685278-24561E5D-520A-46F0-AAD0-E3D07C1DB7E6

Q38685278-67AC8E64-808D-47D1-83B3-C4F4DA8F6526

Q38685278-C0EE89E1-0F1C-4E2A-A574-A51DE8EF327B

P2860

Q38685278-05345888-E9C8-4480-B3A8-1D3AE7ECE962

Q38685278-106A4220-A318-4C2B-8EF1-0B50B9178E2E

Q38685278-120D1C8D-71A0-472A-A1D9-4F1687CBB64C

Q38685278-1559EC85-BD05-4FCE-902B-382DDFB2ADF3

Q38685278-1AC37F8D-8309-4D50-A964-045FDA583169

Q38685278-20A128CC-3EE6-42F1-A90E-A647117DD5AC

Q38685278-280B864A-5573-4FC6-B51E-916BBECF293E

Q38685278-299DC04D-6F77-46F2-AC0F-F338EA2E0777

Q38685278-33451179-16BA-48DF-AE41-1529D72B0E30

Q38685278-3CEED713-F65F-4356-96C1-2A8F26B859F9

P2888

Q38685278-46136709-4881-4AF2-9353-3B927BFF3E10

P304

Q38685278-CCB96D03-F031-46B0-9FEF-6E87514238F7

P31

Q38685278-F8147DB3-6272-4D9D-9DC8-F2A4DE9A0EFF

P356

Q38685278-8807F41E-E2C0-4CBD-A251-07B194D951A4

P433

Q38685278-51D0E18A-BDC4-4B34-A931-603E04439755

P478

Q38685278-E16ED97F-7CDB-4C6B-9EB2-6F59CC8827F0

P577

Q38685278-66C27953-CB71-4457-9ED6-6B4B206AE77A

P6179

Q38685278-05A84ED8-D02F-4D75-9D83-95CC4591ADCB

P698

Q38685278-6176E152-F7D4-4A7A-A428-F47BE7D0F4FB

P356

S40265-017-0748-7

P1433

P1476

Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.

@en

P2093

Joaquim Bellmunt

http://www.w3.org/2001/XMLSchema#string

Kevin T Lundgren

http://www.w3.org/2001/XMLSchema#string

Matthew S Farina

http://www.w3.org/2001/XMLSchema#string

P2860

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

The role of the CD28 receptor during T cell responses to antigen

Comprehensive molecular characterization of urothelial bladder carcinoma

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986

P2888

s40265-017-0748-7

P304

1077-1089

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-017-0748-7

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085388315

http://www.w3.org/2001/XMLSchema#string

P698

28493171

http://www.w3.org/2001/XMLSchema#string